Abstract
Background
Data on antibiotic resistance of uropathogens for urinary tract infection (UTI) recurrences are lacking.
Methods
In a retrospective cohort of adults at Kaiser Permanente Southern California with culture-confirmed index uncomplicated UTI (uUTI) between January 2016 and December 2020, we examined the number and characteristics of subsequent culture-confirmed UTIs through 2021.
Results
We identified 148 994 individuals with a culture-confirmed index uUTI (88% female, 44% Hispanic; mean age, 51 years [standard deviation, 19 years]), of whom 19% developed a subsequent culture-confirmed UTI after a median 300 days (interquartile range, 126–627 days). The proportion of UTI due to Escherichia coli was highest for index uUTI (79%) and decreased to 73% for sixth UTI (UTI 6) (P for trend < .001), while the proportion due to Klebsiella spp increased from index UTI (7%) to UTI 6 (11%) (P for trend < .001). Nonsusceptibility to ≥1 and ≥3 antibiotic classes was observed in 57% and 13% of index uUTIs, respectively, and was higher for subsequent UTIs (65% and 20%, respectively, for UTI 6). Most commonly observed antibiotic nonsusceptibility patterns included penicillins alone (12%), and penicillins and trimethoprim-sulfamethoxazole plus ≥1 additional antibiotic class (9%).
Conclusions
Antibiotic nonsusceptibility is common in UTIs and increases with subsequent UTIs. Continuous monitoring of UTI recurrences and susceptibility patterns is needed to guide treatment decisions.
Keywords: urinary tract infection, antibiotic resistance, uropathogens, antibiotic treatment, antibiotic susceptibility
Among adults with urinary tract infection (UTI) during 2016–2020, 19% had culture-confirmed UTI recurrences, primarily caused by Escherichia coli. Antibiotic nonsusceptibility increased for subsequent UTIs; for the sixth UTI recurrence, 65% and 20% had isolates nonsusceptible to ≥1 and ≥3 antibiotic classes, respectively.
Urinary tract infections (UTIs) are among the most common bacterial infections in the United States (US), primarily affecting women [1]. In the US, half of women experience ≥1 UTI by the age of 35 years, and 1 in 3 women experiences ≥1 UTI requiring antibiotic treatment in her lifetime, with 11% experiencing ≥1 UTI per year [2, 3]. UTI incidence in the US increased by 52% between 1998 and 2011, resulting in 400 000 hospitalizations with an estimated cost of $2.8 billion in 2011 [4]. UTIs have also been increasing in outpatient settings [5] and cause substantial negative impact on activity and health-related quality of life [6].
Uropathogenic Escherichia coli is the most common pathogen causing UTIs. Escherichia coli accounts for up to 80% of uncomplicated UTIs (uUTIs), which typically affect otherwise healthy individuals without underlying structural abnormalities or instrumentation [7–9], and approximately a quarter of complicated UTIs (cUTIs) [10], which occur in the presence of structural abnormalities or instrumentation compromising the urinary tract [11–13]. Other gram-negative pathogens such as Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa and gram-positive pathogens such as Staphylococcus spp, Enterococcus faecalis, and group B Streptococcus can also cause UTIs [7, 9]. Following an initial uUTI, subsequent UTIs are common and may be caused by the same or different pathogens.
Antibiotic treatment for UTI is often empiric without urine culture or susceptibility testing [14, 15], and is usually based on national guidelines and local resistance profiles [15]. The Infectious Diseases Society of America recommends trimethoprim-sulfamethoxazole (TMP-SMX), nitrofurantoin, or fosfomycin as first-line therapy [14]. UTIs also have a high recurrence rate, leading to increased use of antibiotics and antibiotic resistance [16, 17]. Antibiotic resistance in uropathogens has been increasing [18], resulting in increased risk of treatment failure, patient morbidity, healthcare costs, and use of broad-spectrum antibiotics, further exacerbating antibiotic resistance [7, 18, 19].
Given the continued burden of UTIs, current data on repeated occurrence of UTI are needed. Also, despite global increases in multidrug resistance (MDR) [20–22], recent data on antibiotic resistance of uropathogens are lacking, especially antibiotic resistance patterns for those patients experiencing UTI recurrences. Leveraging electronic health records (EHR) from a cohort of individuals with uUTI at Kaiser Permanente Southern California (KPSC), we described the antibiotic resistance of subsequent uUTIs and cUTIs (from 2016–2021) following an initial uUTI (from 2016–2020).
METHODS
Study Setting
This study was conducted at KPSC, a large, integrated healthcare organization serving >4.8 million residents of Southern California, closely mirroring the sociodemographically diverse Southern California population [23]. KPSC's EHR captures all aspects of members' health information, including demographic/socioeconomic characteristics, diagnoses, test results, and medications from all care settings. Standard laboratory tests from specimens collected throughout the region are processed in the 2 centralized regional reference laboratories. Documentation from care received outside KPSC is submitted for reimbursement and integrated into the EHR. This study was approved by the KPSC institutional review board, with a waiver for informed consent.
Study Population and Data Collection
This study leveraged data from a retrospective cohort study of adults with index uUTI during 2016–2020 who were followed through 2021 for subsequent UTI events [5, 24]. To assemble the prior cohort, we first identified all UTI events from EHR by (1) UTI diagnosis code with an antibiotic prescription within ±3 days, or (2) positive urine culture with an antibiotic prescription within ±3 days, or (3) positive urine culture with a diagnosis code within ±7 days (Supplementary Table 1); positive cultures without either a diagnosis code or an antibiotic prescription were excluded as potential asymptomatic bacteriuria. UTIs occurring within 30 days of each other were counted as a single event [5, 24]. Among these, UTIs were then defined as cUTI using a definition adapted from Carreno et al, which defines cUTI based on select International Classification of Diseases, Tenth Revision urologic infection codes, structural abnormalities/obstruction, and procedures (Supplementary Table 1) [25]. All UTIs that were not defined as cUTI were defined as uUTI. The first uUTI during 2016–2020 was defined as the index uUTI. We excluded individuals with <1 year of continuous KPSC membership and those with any UTI in the year prior to index date (date of the index uUTI).
The study population herein consists of a subcohort of individuals from the prior index uUTI cohort, who had a culture-positive index uUTI with an antibiotic prescription and/or a diagnosis code (Supplementary Figure 1). Among this study cohort, we examined index uUTIs (UTI 1), and all subsequent culture-confirmed UTIs (uUTI and cUTI) through 2021. Antibiotic susceptibility data on aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, fosfomycin, nitrofurantoin, penicillins, TMP-SMX, and others were obtained by routine testing of positive urine cultures at KPSC laboratories using VITEK 2 antimicrobial susceptibility cards; this testing is conducted as part of standard of care in the 2 centralized KPSC regional reference laboratories, and results are integrated into the EHR.
Analysis
We described the demographic and clinical characteristics of those with an index uUTI by the number of subsequent UTIs, including sex, age, race/ethnicity, healthcare utilization, and Charlson comorbidity score. We examined the number of index uUTIs and subsequent UTIs, as well as the median time between each UTI, by pathogen identified at index uUTI. We also described the proportion of initial and subsequent UTIs with antibiotic nonsusceptibility (intermediate and resistant) by antibiotic class. We used the Cochran-Armitage trend test to assess for trend across index UTI and subsequent UTIs for each pathogen, as well as each nonsusceptible antibiotic class. Additionally, we reported prior antibiotic exposure (antibiotics dispensed for any reason in the 12 months prior to index date). Finally, we reported the proportion of UTI isolates with antibiotic nonsusceptibility by the number of nonsusceptible antibiotic classes, and for each UTI (for UTI 1, 2, 3, etc) during the study period, including MDR (intermediate or resistant to ≥3 antibiotic classes) patterns. All analyses were conducted using SAS version 9.4 and Enterprise Guide version 8.2 software (SAS Institute, Cary, North Carolina).
RESULTS
We identified 777 817 adults with ≥1 UTI event during 2015–2021, with ≥1-year KPSC membership prior to index date (Supplementary Figure 1), of whom 475 013 had ≥1 uUTI during 2016–2020. After applying exclusion criteria, the final cohort included 148 994 individuals who had a culture-confirmed index uUTI between 1 January 2016 and 31 December 2020.
Characteristics of the UTI Cohort
The overall cohort was 88% female and 44% Hispanic, with a mean age of 50 years (standard deviation, 19 years) (Table 1). The cohort included 111 784 individuals who experienced 1 uUTI only, 31 754 with 2–3 UTIs, 4203 with 4–5 UTIs, and 1253 with ≥6 UTIs during the study period. The proportion that was female and the mean age were higher for each subsequent UTI. Those with 1 uUTI only were most commonly Hispanic (45%) followed by White (34%), and those with ≥6 UTIs were most commonly White (48%) and Hispanic (39%), reflecting the race/ethnicity distribution of the older KPSC members. Individuals with 1 uUTI only were most commonly covered by commercial insurance (66%), then Medicare (23%), while those with ≥6 UTIs were most commonly covered by Medicare (57%), then commercial insurance (36%). Charlson scores, number of outpatient/emergency department/inpatient visits, and the number of antibiotics dispensed in the year prior to index UTI were higher for individuals with more subsequent UTIs experienced during the study period.
Table 1.
Characteristics of Individuals With Culture-Confirmed Urinary Tract Infection (UTI), by Number of UTIs, Kaiser Permanente Southern California, 2016–2020
| Characteristics | No. of UTIs | |||
|---|---|---|---|---|
| 1 UTI | 2–3 UTIs | 4–5 UTIs | ≥6 UTIs | |
| n = 111 784 | n = 31 754 (2 UTIs = 24 292; 3 UTIs = 7462) |
n = 4203 (4 UTIs = 2940; 5 UTIs = 1263) |
n = 1253 | |
| Demographic/clinical | ||||
| Female sexa | 97 736 (87.4) | 28 849 (90.9) | 3909 (93.0) | 1174 (93.7) |
| Age, ya | ||||
| Mean (SD) | 49.5 (19.1) | 55.1 (19.8) | 61.1 (18.5) | 65.5 (16.6) |
| Median (range) | 49 (18–106) | 57 (18–103) | 65 (18–100) | 68 (18–98) |
| Age group, ya | ||||
| 18–30 | 23 075 (20.6) | 4769 (15.0) | 370 (8.8) | 57 (4.6) |
| 31–40 | 17 151 (15.3) | 3635 (11.5) | 337 (8.0) | 65 (5.2) |
| 41–50 | 17 548 (15.7) | 4159 (13.1) | 395 (9.4) | 101 (8.1) |
| 51–60 | 19 177 (17.2) | 5180 (16.3) | 663 (15.8) | 164 (13.1) |
| 61–70 | 17 528 (15.7) | 6084 (19.2) | 909 (21.6) | 314 (25.1) |
| ≥71 | 17 305 (15.5) | 7927 (25.0) | 1529 (36.4) | 552 (44.1) |
| Race/ethnicitya | ||||
| Hispanic | 49 784 (44.5) | 14 036 (44.2) | 1832 (43.6) | 489 (39.0) |
| White | 38 400 (34.4) | 11 828 (37.3) | 1739 (41.4) | 602 (48.0) |
| Asian/Pacific Islander | 11 750 (10.5) | 2877 (9.1) | 284 (6.8) | 73 (5.8) |
| Black | 8443 (7.6) | 2329 (7.3) | 285 (6.8) | 71 (5.7) |
| Other/unknown | 3407 (3.1) | 684 (2.2) | 63 (1.5) | 18 (1.4) |
| Body mass indexb, kg/m2 | ||||
| <18.5 (underweight) | 1800 (1.6) | 544 (1.7) | 57 (1.4) | 15 (1.2) |
| 18.5–24.9 (healthy weight) | 30 810 (27.6) | 8990 (28.3) | 1111 (26.4) | 291 (23.2) |
| 25.0–29.9 (overweight) | 31 441 (28.1) | 9341 (29.4) | 1304 (31.0) | 422 (33.7) |
| 30.0–39.9 (obese) | 28 787 (25.8) | 8788 (27.7) | 1288 (30.6) | 396 (31.6) |
| >39.9 (extremely obese) | 6648 (6.0) | 2022 (6.4) | 290 (6.9) | 92 (7.3) |
| Unknown | 12 298 (11.0) | 2069 (6.5) | 153 (3.6) | 37 (3.0) |
| Smoking statusb | ||||
| Never | 73 274 (65.6) | 21 258 (67.0) | 2761 (65.7) | 815 (65.0) |
| Former | 16 039 (14.4) | 5626 (17.7) | 931 (22.2) | 319 (25.5) |
| Current | 5715 (5.1) | 1439 (4.5) | 175 (4.2) | 37 (3.0) |
| Unknown | 16 756 (15.0) | 3431 (10.8) | 336 (8.0) | 82 (6.5) |
| Neighborhood-level incomeb | ||||
| <$40 000 | 4181 (3.7) | 1168 (3.7) | 147 (3.5) | 46 (3.7) |
| $40 000–$59 999 | 20 513 (18.4) | 5731 (18.1) | 787 (18.7) | 239 (19.1) |
| $60 000–$84 999 | 34 008 (30.4) | 9623 (30.3) | 1247 (29.7) | 386 (30.8) |
| ≥$85 000 | 52 454 (46.9) | 15 084 (47.5) | 2011 (47.9) | 580 (46.3) |
| Unknown | 628 (0.6) | 148 (0.5) | 11 (0.3) | 2 (0.2) |
| Insuranceb | ||||
| Commercial | 73 540 (65.8) | 17 493 (55.1) | 1811 (43.1) | 452 (36.1) |
| Medicare | 25 417 (22.7) | 11 042 (34.8) | 2040 (48.5) | 715 (57.1) |
| Medicaid | 7006 (6.3) | 1907 (6.2) | 223 (5.3) | 53 (4.2) |
| Private pay | 5735 (5.1) | 1226 (3.9) | 128 (3.1) | 33 (2.6) |
| Other | 21 (<0.1) | 6 (<0.1) | 0 | 0 |
| Uninsured | 65 (0.1) | 17 (<0.1) | 1 (<0.1) | 0 |
| No. of Charlson comorbiditiesc | ||||
| 0 | 70 834 (63.4) | 16 292 (51.3) | 1642 (39.1) | 365 (29.1) |
| 1–2 | 33 211 (29.7) | 11 804 (37.2) | 1782 (42.4) | 621 (49.6) |
| ≥3 | 7739 (6.9) | 3658 (11.5) | 779 (18.5) | 267 (21.3) |
| Comorbiditiesc | ||||
| Diabetes | 17 857 (16.0) | 7196 (22.7) | 1228 (29.2) | 442 (35.3) |
| Renal disease | 8068 (7.2) | 3623 (11.4) | 714 (17.0) | 244 (19.5) |
| Dementia | 1740 (1.6) | 771 (2.4) | 143 (3.4) | 32 (2.6) |
| Immunocompromised | 2727 (2.4) | 1105 (3.5) | 228 (5.4) | 78 (6.2) |
| Pregnancya | 2439 (2.2) | 690 (2.2) | 54 (1.3) | 10 (0.8) |
| Healthcare utilizationc | ||||
| No. of outpatient visits | ||||
| 0 | 6534 (5.9) | 1035 (3.3) | 60 (1.4) | 10 (0.8) |
| 1–4 | 35 700 (31.9) | 7709 (24.3) | 732 (17.4) | 161 (12.9) |
| 5–8 | 26 171 (23.4) | 7323 (23.1) | 847 (20.2) | 227 (18.1) |
| 9–15 | 23 001 (20.6) | 7599 (23.9) | 1060 (25.2) | 334 (26.7) |
| ≥16 | 20 378 (18.2) | 8088 (25.5) | 1504 (35.8) | 521 (41.6) |
| No. of ED visits | ||||
| 0 | 90 252 (80.7) | 24 384 (76.8) | 3028 (72.0) | 888 (70.9) |
| 1 | 15 446 (13.8) | 4948 (15.6) | 781 (18.6) | 236 (18.8) |
| ≥2 | 6086 (5.4) | 2422 (7.6) | 394 (9.4) | 129 (10.3) |
| No. of inpatient visits | ||||
| 0 | 102 899 (92.1) | 28 649 (90.2) | 3678 (87.5) | 1081 (86.3) |
| 1 | 7005 (6.3) | 2345 (7.4) | 386 (9.2) | 134 (10.7) |
| ≥2 | 1880 (1.7) | 760 (2.4) | 139 (3.3) | 38 (3.0) |
| Antibiotics dispensedc | ||||
| No. of antibiotic classes dispensed (for all indications) | ||||
| 0 | 75 328 (67.4) | 19 316 (60.8) | 2322 (55.3) | 631 (50.4) |
| 1–2 | 28 977 (25.9) | 9406 (29.7) | 1323 (31.5) | 409 (32.6) |
| ≥3 | 7479 (6.7) | 3032 (9.6) | 558 (13.3) | 213 (17.0) |
| Antibiotic class | ||||
| Cephalosporin | 18 000 (16.1) | 6481 (20.4) | 971 (23.1) | 360 (28.7) |
| Fluoroquinolone | 5045 (4.5) | 2240 (7.1) | 452 (10.8) | 176 (14.1) |
| Nitrofurantoin | 1646 (1.5) | 729 (2.3) | 165 (3.9) | 64 (5.1) |
| Aminoglycoside | 648 (0.6) | 208 (0.7) | 33 (0.8) | 14 (1.1) |
| Carbapenem | 77 (0.1) | 37 (0.1) | 7 (0.2) | 1 (0.1) |
| Fosfomycin | 11 (0.0) | 9 (0.0) | 2 (0.1) | 4 (0.3) |
| Other | 1154 (1.0) | 486 (1.5) | 83 (2.0) | 24 (1.9) |
| Year of index UTI | ||||
| 2016 | 21 920 (19.6) | 9046 (28.5) | 1695 (40.3) | 685 (54.7) |
| 2017 | 23 185 (20.7) | 8100 (25.5) | 1216 (28.9) | 337 (26.9) |
| 2018 | 23 423 (21.0) | 6704 (21.1) | 779 (18.5) | 163 (13.0) |
| 2019 | 24 791 (22.2) | 5135 (16.2) | 402 (9.6) | 54 (4.3) |
| 2020 | 18 465 (16.5) | 2769 (8.7) | 111 (2.6) | 14 (1.1) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ED, emergency department; SD, standard deviation; UTI, urinary tract infection.
aAt index date.
bMost recent in the 12 months prior to index date.
cIn the 12 months prior to index date.
Characteristics of UTIs
Overall, the proportion of individuals with urine culture obtained and those testing positive at each UTI remained largely unchanged from index uUTI through UTI 6 (Supplementary Table 2). Of the 148 994 individuals with an index uUTI, 66 607 (45%) had a subsequent UTI (diagnosis code with antibiotic prescription, or positive culture with diagnosis code or antibiotic prescription), of which 28 007 (42% of 66 607 and 19% of 148 994) were culture-confirmed with susceptibility results. Among the 28 007 UTI 2 meeting inclusion criteria for our study, the median time between index uUTI and UTI 2 was 300 days (interquartile range [IQR], 126–627 days), and 7250 (26%) developed an additional UTI (UTI 3) after a median 209 days (IQR, 93–428 days) (Supplementary Table 3). The median number of days between UTI 3 and 4, UTI 4 and 5, and UTI 5 and 6 was 160 (IQR, 77.5–341), 140 (IQR, 74–288), and 126 (IQR, 65–247), respectively. Duration between each culture-confirmed UTI was similar when stratified by pathogen isolated at index uUTI. cUTIs accounted for 11% of all subsequent UTIs.
Overall, E coli was the most common pathogen identified for index and all subsequent UTIs (Table 2). At index uUTI, E coli was identified in 117 955 (79%) individuals, followed by Klebsiella (10 192 [7%]). From the index uUTI to UTI 6, the proportion of E coli UTI decreased from 79% to 73% (P for trend <.001) while the proportion of Klebsiella spp UTI increased from 7% to 11% (P for trend <.001).
Table 2.
Distribution of Pathogens Identified in Urinary Tract Infections, 2016–2021
| Pathogen | UTI, No. (%) | P for Trend | |||||
|---|---|---|---|---|---|---|---|
| UTI 1 (Index uUTI) |
UTI 2 | UTI 3 | UTI 4 | UTI 5 | UTI 6 | ||
| Escherichia coli | 117 955 (79.2) | 21 416 (76.5) | 10 140 (75.0) | 5435 (73.0) | 3099 (72.0) | 1895 (72.7) | <.001 |
| Klebsiella | 10 192 (6.8) | 2436 (8.7) | 1324 (9.8) | 780 (10.5) | 482 (11.2) | 282 (10.8) | <.001 |
| Proteus mirabilis | 6305 (4.2) | 1339 (4.8) | 596 (4.4) | 332 (4.5) | 165 (3.8) | 100 (3.8) | .63 |
| Multiple | 2963 (2.0) | 745 (2.7) | 415 (3.1) | 281 (3.8) | 179 (4.2) | 98 (3.8) | <.001 |
| Othersa | 11 579 (7.8) | 2033 (7.3) | 1035 (7.7) | 607 (8.2) | 381 (8.8) | 232 (8.9) | .03 |
| Total | 148 994 | 27 969 | 13 510 | 7435 | 4306 | 2607 | NA |
Abbreviations: NA, not applicable; UTI, urinary tract infection; uUTI, uncomplicated urinary tract infection.
aDoes not include contaminants.
Prior Antibiotic Exposure
In the year prior to the index uUTI, the most common antibiotic class dispensed for any reason was penicillins (16%), followed by first-generation cephalosporins (13%) and fluoroquinolones (5%) (Figure 1, Supplementary Table 4). In the year prior to each subsequent UTI, first-generation cephalosporins and fluoroquinolones were the most commonly dispensed, followed by penicillins and nitrofurantoin.
Figure 1.
Proportion of individuals with culture-confirmed urinary tract infection (UTI) with antibiotics dispensed in 12 months prior to each UTI (all pathogens), Kaiser Permanente Southern California, 2015–2020.
Antibiotic Nonsusceptibility
Among the index uUTIs, 84 929 (57%) were nonsusceptible to ≥1 antibiotic class, and 18 595 (13%) to ≥3 antibiotic classes (Table 3; shown for E coli UTI only in Supplementary Table 5). For index uUTIs, nonsusceptibility to penicillins (48%) and TMP-SMX (20%) was most common, followed by nitrofurantoin (15%) and first-generation cephalosporins (9%).
Table 3.
Proportion of Culture-Confirmed Urinary Tract Infections by Nonsusceptibility to Antibiotic Classes, 2016–2020a
| Antibiotic Class | UTI, No. (%) | ||||||
|---|---|---|---|---|---|---|---|
| UTI 1/Index uUTI (n = 148 994) | UTI 2 (n = 28 007) | UTI 3 (n = 13 522) | UTI 4 (n = 7444) | UTI 5 (n = 4310) | UTI 6 (n = 2609) | P for Trend | |
| Any antibiotic class | 84 929 (57.0) | 16 954 (60.5) | 8371 (61.9) | 4750 (63.8) | 2824 (65.5) | 1698 (65.1) | <.001 |
| ≥3 antibiotic classes | 18 595 (12.5) | 4139 (14.8) | 2221 (16.4) | 1337 (18.0) | 850 (19.7) | 509 (19.5) | <.001 |
| Penicillinsb | 71 643 (48.1) | 14 069 (50.2) | 6927 (51.2) | 3928 (52.8) | 2365 (54.9) | 1418 (54.4) | <.001 |
| TMP-SMX | 30 183 (20.3) | 6001 (21.4) | 2942 (21.8) | 1726 (23.2) | 1013 (23.5) | 615 (23.6) | <.001 |
| Nitrofurantoin | 21 618 (14.5) | 4601 (16.4) | 2318 (17.1) | 1386 (18.6) | 837 (19.4) | 479 (18.4) | <.001 |
| Cephalosporins | 13 705 (9.2) | 2850 (10.2) | 1614 (11.9) | 950 (12.8) | 630 (14.6) | 365 (14.0) | <.001 |
| 1st generation | 13 647 (9.2) | 2837 (11.8) | 1601 (11.8) | 940 (12.6) | 625 (14.5) | 361 (13.8) | <.001 |
| 2nd generation | 0 | 0 | 0 | 0 | 0 | 0 | NA |
| 3rd generation | 30 (0.02) | 7 (0.02) | 4 (0.07) | 5 (0.07) | 4 (0.09) | 2 (0.08) | <.001 |
| 4th generation | 28 (0.02) | 6 (0.02) | 9 (0.07) | 5 (0.07) | 1 (0.02) | 2 (0.08) | <.001 |
| Fluroquinolones | 13 039 (8.8) | 3629 (13.0) | 2049 (15.2) | 1268 (17.0) | 824 (19.1) | 511 (19.6) | <.001 |
| Aminoglycosides | 8863 (6.0) | 1976 (7.1) | 1018 (7.5) | 573 (7.7) | 350 (8.1) | 229 (8.8) | <.001 |
| Lincomycin | 474 (0.3) | 84 (0.3) | 44 (0.3) | 25 (0.3) | 18 (0.4) | 13 (0.5) | .16 |
| Tetracyclines | 299 (0.2) | 48 (0.2) | 15 (0.1) | 16 (0.2) | 6 (0.1) | 7 (0.3) | .32 |
| Carbapenems | 122 (0.1) | 34 (0.1) | 20 (0.2) | 17 (0.2) | 10 (0.2) | 11 (0.4) | <.001 |
| Rifamycin | 5 (0) | 0 | 0 | 0 | 0 | 0 | .26 |
| Chloramphenicol | 3 (0) | 0 | 0 | 0 | 0 | 0 | .39 |
| Macrolides | 4 (0) | 0 | 0 | 0 | 0 | 0 | .32 |
| Otherc | 140 (0.1) | 43 (0.2) | 35 (0.3) | 14 (0.2) | 16 (0.4) | 7 (0.3) | <.001 |
Abbreviations: NA, not applicable; TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection; uUTI, uncomplicated UTI.
aShown for Escherichia coli UTI in Supplementary Table 5.
bIncludes amoxicillin, amoxicillin-clavulanate, ampicillin, ampicillin-sulbactam, dicloxacillin, nafcillin, oxacillin, and piperacillin-tazobactam.
cIncludes aztreonam, colistin, fosfomycin, daptomycin, linezolid, tigecycline, and vancomycin.
The proportion of isolates with antibiotic nonsusceptibility increased for subsequent UTIs (P for trend <.001); at UTI 6, 65% were nonsusceptible to ≥1 antibiotic class and 20% were nonsusceptible to ≥3 antibiotic classes (Figure 2, Supplementary Table 6). The proportion of isolates nonsusceptible to penicillins, TMP-SMX, nitrofurantoin, fluroquinolones, cephalosporins, aminoglycosides, and carbapenems increased for subsequent UTIs (P for trend <.001). Among all isolates nonsusceptible to ≥1 antibiotic class, 8% were “intermediate” and 92% were “resistant” (Supplementary Table 7).
Figure 2.
Proportion of nonsusceptible isolates, by the number of nonsusceptible antibiotic classes by urinary tract infection (UTI) event (all pathogens combined), 2016–2020.
Among antibiotics commonly used for UTIs (penicillins, nitrofurantoin, TMP-SMX, fluoroquinolones, aminoglycosides, and first-generation cephalosporins), nonsusceptibility to 1 antibiotic class only was observed in 24% of index uUTIs (Figure 3). Nonsusceptibility to 2 antibiotic classes was observed in 22%. MDR was observed in 13% of index uUTIs (nonsusceptibility to 3 antibiotic classes [9%], 4 antibiotic classes [3%], 5 antibiotic classes [1%], ≥6 antibiotic classes [<1.0%]); 42% of all isolates from index uUTIs were susceptible to all included antibiotic classes. The most common nonsusceptibility patterns included nonsusceptibility to penicillins and TMP-SMZ (9%), and to penicillins and nitrofurantoin (6%). MDR patterns including penicillins was common (12%), and MDR patterns involving penicillins and TMP-SMX plus ≥1 antibiotic class accounted for 9% of all observed resistance patterns.
Figure 3.
Antibiotic nonacceptability patterns of culture-confirmed urinary tract infections (UTIs), 2016–2020. Rows with index UTI (UTI 1) count <50 not shown. Only up to sixth UTI (UTI 6) shown due to low counts for subsequent UTIs. Abbreviations: AGS, aminoglycoside; CSP, cephalosporin; FLQ, fluoroquinolone; NFT, nitrofurantoin; PNC, penicillin; T-S, trimethoprim and sulfamethoxazole; UTI, urinary tract infection.
For subsequent UTIs, nonsusceptibility patterns were similar, with the most common nonsusceptibility to 2 antibiotic classes including penicillins and TMP-SMZ (7%–9%) and penicillins and nitrofurantoin (7%–9%). However, the prevalence of nonsusceptibility gradually increased for subsequent UTIs. For UTI 6, nonsusceptibility to 1 antibiotic class only was observed in 17%, and nonsusceptibility to 2 antibiotic classes in 19%. Nonsusceptibility to 3, 4, 5, and 6 antibiotic classes was observed in 15%, 7%, 2%, and 1% of UTI 6 isolates, respectively (not counting patterns with isolate counts <5); 30% were susceptible to all antibiotic classes.
DISCUSSION
In this study, among a large cohort of adults with culture-confirmed index uUTI during 2016–2020, we characterized uropathogens and patterns of antibiotic nonsusceptibility for index and subsequent culture-confirmed UTIs. Escherichia coli was the most common uropathogen overall, with UTIs due to other pathogens including Klebsiella and Proteus mirabilis increasingly common at subsequent events. About 1 in 5 individuals with an index uUTI developed a subsequent UTI within 10 months, although the time between the index and subsequent UTIs varied widely. Among those with ≥1 subsequent UTI, 1 in 4 developed an additional UTI after about 7 months of the second UTI. Penicillins and TMP-SMX were most commonly responsible for both single and multiple class antibiotic nonsusceptibility. For subsequent UTIs, nonsusceptibility patterns were similar, but the proportion of nonsusceptible isolates gradually increased.
Escherichia coli has been frequently reported as the dominant pathogen for both uUTIs and cUTIs, with Enterococcus spp and Candida spp substantially more common in cUTIs [16]. Studies have reported that after an initial UTI, 27% of women experienced recurrence within 6 months, and 3% had a second recurrence within the same period of time [26, 27]. In a study in the primary care setting, 53% of women ≥55 years of age and 36% of younger women reported a recurrence within 1 year of an initial UTI [28]. More recent data from a multicenter Dutch nursing home study reported recurrence by the same E coli strain after several months up to over 400 days after the initial UTI [29]. We observed that among individuals with a culture-confirmed index uUTI, about 34% had ≥2 subsequent UTIs during the study period. After the index UTI, about 20% experienced a second UTI after about 10 months, with additional UTIs occurring in 4- to 7-month intervals in about 25% of those who experienced a second UTI. Long time intervals between UTIs may be because we only included culture-confirmed UTIs, and not UTIs identified only by diagnosis codes with antibiotics. The long intervals may also be partially explained by some strains of uropathogens colonizing the bladder for longer periods or recolonization by the same or a different strain [29].
Since the 1940s, various antibiotics have been recommended for treatment of UTIs [30]. However, growing antibiotic resistance has contributed to recurrence and chronicity of UTIs, making UTI treatment increasingly complicated. A substantial increase in UTIs resistant to penicillins and TMP-SMX has been reported [31, 32]. Co-resistance to ampicillin and TMP-SMX, and MDR involving ampicillin, TMP-SMX, and ciprofloxacin have also been commonly reported in the US [33–35]. US surveillance data from 2000 reported MDR in 7% of E coli, including resistance to ampicillin (98%), TMP-SMX (93%), cephalosporin (87%), ciprofloxacin (39%), and nitrofurantoin (8%) among the resistant isolates [33]. More recently, a study from Italy of >30 000 E coli urine isolates found that resistance to commonly prescribed antibiotics increased significantly between 2000 and 2019 with isolates collected from 2015 to 2019 having 30% resistance to ciprofloxacin, 24% to TMP-SMX, and >10% to third-generation cephalosporins with 17% MDR and 12% extended-spectrum β-lactamase (ESBL) producers [36]. Another study evaluating MDR among expanded-spectrum cephalosporin-resistant Enterobacterales (ESCR-E) found that 91% of ESCR-E uropathogenic E coli (UPEC) causing UTI had an ESBL phenotype. Furthermore, ESCR-E UPEC with ESBL was 1.7 times more likely to be MDR than non-ESBL isolates [37].
Similar to prior findings, in our data, the most common nonsusceptibility patterns included nonsusceptibility to penicillins and TMP-SMZ (9%), nonsusceptibility to penicillins and nitrofurantoin (6%), and MDR involving penicillins (9%). Although nitrofurantoin resistance remained low in most settings since 2000 (∼2%) [24, 38], we observed a high prevalence of nonsusceptibility to nitrofurantoin (>14%). Increased use of nitrofurantoin among the recommended first-line antibiotics for UTI may help explain the high nonsusceptibility. The change in susceptibility may also be explained by change in causative bacteria (eg, decreasing proportion with E coli and increasing proportion with Klebsiella). Also, our definition of “nonsusceptibility” included “intermediate.” Of all isolates nonsusceptible to ≥1 antibiotic class, about 9% were “intermediate.” Among isolates nonsusceptible to nitrofurantoin, about half were “intermediate.” As such, varying definitions of antibiotic resistance used in previous studies (eg, definition of “nonsusceptibility” with or without including “intermediate”) may partially explain the difference.
Less is known about antibiotic resistance of recurrent UTI (rUTI). Studies have shown that most recurrences have been associated with specific antibiotic resistance traits and sequence types [39]. A study of rUTIs in nursing home residents showed that the recurrences were caused by both the same and different strains of E coli or other uropathogens [29]. In our data on UTI recurrences, we observed that the prevalence of both single antibiotic nonsusceptibility and MDR gradually increased with subsequent UTIs. Nonsusceptibility to any antibiotic class increased from 57% at index uUTI to 65% at UTI 6. More importantly, MDR increased from 13% at index uUTI to 20% at UTI 6. Nonsusceptibility to each antibiotic class increased for most tested antibiotic classes including penicillins, TMP-SMX, nitrofurantoin, fluroquinolones, and cephalosporins. Such increases are likely due to increased exposure to antibiotics used to treat previous UTIs. Even short courses of antibiotics impact the microbial flora of the perineal and gastrointestinal tract, the major sources of uropathogens, often selecting for resistant pathogens and increasing the risk of subsequent UTIs due to resistant organisms [7].
Our study has several limitations. First, we did not have sequence data for different strains of uropathogens. Therefore, for cases in which subsequent UTIs were caused by the same pathogen, we could not determine whether the subsequent UTIs were due to relapse of the same strain or a new infection by a different strain of the same uropathogen. Second, while we observed an increase in nonsusceptibility with subsequent UTIs, some may have been cases of asymptomatic bacteriuria; however, we only included positive cultures with a diagnosis code and/or an antibiotic prescription that were considered UTIs by KPSC clinicians. Third, we evaluated nonsusceptibility patterns at the level of antibiotic class, grouping some antibiotic classes with a range of antimicrobial coverage into 1 class (ie, penicillins). Antibiotic drugs within the same antibiotic class typically share the same mechanisms of resistance; thus, our findings on most antibiotic classes can be applied broadly in the clinical setting. We also did not evaluate dose and duration of antibiotics, which could contribute to nonsusceptibility. Fourth, although UTI symptoms usually prompt seeking of medical care, our cohort may have missed some cases that were not medically attended. Also, because the volume of clinical visits and laboratory testing substantially decreased during the coronavirus disease 2019 pandemic, sample size was small in 2020. Data from this period may also have captured more severe cases who were more likely to seek care and have a culture ordered. In addition, health-seeking behaviors that potentially have an impact on both development of antibiotic resistance and UTIs may be different in those who have a urine culture and those who do not. By focusing our study on individuals with a urine culture, our patient population may have been more likely than the general population to have had recent UTI or history of antibiotic-resistant UTI, which could overestimate resistance. Last, rUTIs are often defined as ≥3 UTI events within 1 year or ≥2 UTI events in the last 6 months [15]. We did not adopt a formal definition for rUTI because our goal was to examine characteristics of all culture-confirmed UTI occurring during the study period.
Increasing antibiotic resistance limits antibiotic options for outpatient treatment of UTIs and renders antibiotic treatment less effective. As repeated UTIs are a major cause of antibiotic resistance, a better understanding of uropathogens responsible for recurrence is needed. Importantly, given that antibiotic therapy for UTI is empiric and uropathogens increasingly demonstrate nonsusceptibility, continuously updated data on susceptibility patterns are critical to guide appropriate antibiotic prescribing as well as to inform interventions to prevent UTI recurrence. As the degree of resistance to the most frequently prescribed antibiotics for UTI evolves over time and may vary by region, it is also important to continuously monitor the local prevalence of uropathogens and their susceptibility to guide appropriate antibiotic use.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
Supplementary Material
Contributor Information
Jennifer H Ku, Department of Research and Evaluation, Kaiser Permanente Southern California.
Sara Y Tartof, Department of Research and Evaluation, Kaiser Permanente Southern California; Kaiser Permanente Southern California and Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
Richard Contreras, Department of Research and Evaluation, Kaiser Permanente Southern California.
Bradley K Ackerson, Department of Research and Evaluation, Kaiser Permanente Southern California.
Lie H Chen, Department of Research and Evaluation, Kaiser Permanente Southern California.
Iris A C Reyes, Department of Research and Evaluation, Kaiser Permanente Southern California.
Michele Pellegrini, GlaxoSmithKline, Siena, Italy.
Johannes E Schmidt, GlaxoSmithKline, Siena, Italy.
Katia J Bruxvoort, Department of Epidemiology, University of Alabama at Birmingham.
Notes
Acknowledgments. The authors thank Pooja M. Patel, MPH, and Rossy F. Perez for their assistance in drafting the manuscript.
Financial support. This study was supported by GlaxoSmithKline (GSK).
References
- 1. Ahmed NH, Hussain T, Biswal I. Comparison of etiological agents and resistance patterns of the pathogens causing community acquired and hospital acquired urinary tract infections. J Glob Infect Dis 2014; 6:135–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000; 10:509–15. [DOI] [PubMed] [Google Scholar]
- 3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28:1–13. [DOI] [PubMed] [Google Scholar]
- 4. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998–2011. Open Forum Infect Dis 2017; 4:ofw281. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Bruxvoort KJ, Bider-Canfield Z, Casey JA, et al. Outpatient urinary tract infections in an era of virtual healthcare: trends from 2008 to 2017. Clin Infect Dis 2020; 71:100–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Thompson J, Marijam A, Mitrani-Gold FS, Wright J, Joshi AV. Activity impairment, health-related quality of life, productivity, and self-reported resource use and associated costs of uncomplicated urinary tract infection among women in the United States. PLoS One 2023; 18:e0277728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7:653–60. [DOI] [PubMed] [Google Scholar]
- 8. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430–41. [DOI] [PubMed] [Google Scholar]
- 9. Tabasi M, Karam MR, Habibi M, Mostafavi E, Bouzari S. Genotypic characterization of virulence factors in Escherichia coli isolated from patients with acute cystitis, pyelonephritis and asymptomatic bacteriuria. J Clin Diagn Res 2016; 10:DC01–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 2016; 37:1288–301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP Jr. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis 2020; 7:ofz536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113(Suppl 1A):5–13. [DOI] [PubMed] [Google Scholar]
- 13. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis Rep 2008; 10:499–504. [DOI] [PubMed] [Google Scholar]
- 14. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103–20. [DOI] [PubMed] [Google Scholar]
- 15. Bonkat G, Bartoletti R, Bruyère F, et al. EAU guidelines on urological infections. 2020. https://uroweb.org/guideline/urological-infections/. Accessed 10 December 2023.
- 16. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13:269–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Valentine-King MA, Trautner BW, Zoorob RJ, et al. Analysis of recurrent urinary tract infection management in women seen in outpatient settings reveals opportunities for antibiotic stewardship interventions. Antimicrob Steward Healthc Epidemiol 2022; 2:e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management. Clin Infect Dis 2021; 73:1992–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis 2016; 63:960–5. [DOI] [PubMed] [Google Scholar]
- 20. Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Von Vietinghoff S, Shevchuk O, Dobrindt U, et al. The global burden of antimicrobial resistance—urinary tract infections. Nephrol Dial Transplant 2024; 39:581–8. [DOI] [PubMed] [Google Scholar]
- 22. Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant gram-negative bacteria causing urinary tract infections: a review. J Chemother 2017; 29(Suppl 1):2–9. [DOI] [PubMed] [Google Scholar]
- 23. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012; 16:37–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Ku JH, Bruxvoort KJ, Salas SB, et al. Multidrug resistance of Escherichia coli from outpatient uncomplicated urinary tract infections in a large United States integrated healthcare organization. Open Forum Infect Dis 2023; 10:ofad287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP Jr. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract Infection. Open Forum Infect Dis 2019; 6:ofz446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol 2019; 11:1756287219832172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80:331–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in women. Int Urogynecol J 2015; 26:795–804. [DOI] [PubMed] [Google Scholar]
- 29. Hidad S, van der Putten B, van Houdt R, Schneeberger C, Kuil SD. Recurrent E. coli urinary tract infections in nursing homes: insight in sequence types and antibiotic resistance patterns. Antibiotics (Basel) 2022; 11:1638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Zhou Y, Zhou Z, Zheng L, et al. Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options. Int J Mol Sci 2023; 24:10537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Gupta K, Hooton TM, Wobbe CL, Stamm WE. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int J Antimicrob Agents 1999; 11(3–4):305–8. [DOI] [PubMed] [Google Scholar]
- 32. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999; 281:736–8. [DOI] [PubMed] [Google Scholar]
- 33. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001; 45:1402–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46:2540–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44:1089–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Milano A, Sulejmani A, Intra J, Sala MR, Leoni V, Carcione D. Antimicrobial resistance trends of Escherichia coli isolates from outpatient and inpatient urinary infections over a 20-year period. Microb Drug Resist 2022; 28:63–72. [DOI] [PubMed] [Google Scholar]
- 37. Jackson N, Belmont CR, Tarlton NJ, et al. Genetic predictive factors for nonsusceptible phenotypes and multidrug resistance in expanded-spectrum cephalosporin-resistant uropathogenic Escherichia coli from a multicenter cohort: insights into the phenotypic and genetic basis of coresistance. mSphere 2022; 7:e0047122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Hammond A, Stuijfzand B, Avison MB, Hay AD. Antimicrobial resistance associations with national primary care antibiotic stewardship policy: primary care-based, multilevel analytic study. PLoS One 2020; 15:e0232903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Li D, Reid CJ, Kudinha T, Jarocki VM, Djordjevic SP. Genomic analysis of trimethoprim-resistant extraintestinal pathogenic Escherichia coli and recurrent urinary tract infections. Microb Genom 2020; 6:mgen000475. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.